Pharmacological treatment of cachexia: any progress?
In view of the renewed interest in pharmacological treatment of anorexia-cachexia in cancer patients over the past 3 years, both the established drugs used in its treatment and the emerging new drugs still being tested for it are reviewed. Results of trials that have already been evaluated are reported, and possible areas for further research are indicated.
Bruera
E
E
Division of Palliative Care Medicine, University of Alberta, Edmonton, Canada.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000932:Antiemetics / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D019167:Appetite Stimulants / Q000627:therapeutic use; D002100:Cachexia / Q000188:drug therapy* / Q000209:etiology; D002976:Clenbuterol / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D019290:Megestrol Acetate / Q000627:therapeutic use; D008550:Melatonin / Q000627:therapeutic use; D008787:Metoclopramide / Q000627:therapeutic use; D009369:Neoplasms / Q000150:complications*; D013792:Thalidomide / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D000932:Antiemetics; D000975:Antioxidants; D019167:Appetite Stimulants; D007166:Immunosuppressive Agents; D013792:Thalidomide; D008550:Melatonin; D008787:Metoclopramide; D019290:Megestrol Acetate; D002976:Clenbuterol